Pathogenic mechanisms of pulmonary arterial hypertension

被引:201
作者
Chan, Stephen Y. [1 ,2 ]
Loscalzo, Joseph [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA
关键词
pulmonary arterial hypertension; molecular mechanism; vasoconstriction; thrombosis; proliferation; genetic association; acquired risk; vascular effector;
D O I
10.1016/j.yjmcc.2007.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary arterial hypertension (PAH) is a complex disease that causes significant morbidity and mortality and is clinically characterized by an increase in pulmonary vascular resistance. The histopathology is marked by vascular proliferation/fibrosis, remodeling, and vessel obstruction. Development of PAH involves the complex interaction of multiple vascular effectors at all anatomic levels of the arterial wall. Subsequent vasoconstriction, thrombosis, and inflammation ensue, leading to vessel wall remodeling and cellular hyperproliferation as the hallmarks of severe disease. These processes are influenced by genetic predisposition as well as diverse endogenous and exogenous stimuli. Recent studies have provided a glimpse at certain molecular pathways that contribute to pathogenesis; these have led to the identification of attractive targets for therapeutic intervention. We will review our current understanding of the mechanistic underpinnings of the genetic and exogenous/acquired triggers of PAH. The resulting imbalance of vascular effectors provoking pathogenic vascular changes will also be discussed, with an emphasis on common and overarching regulatory pathways that may relate to the primary triggers of disease. The current conceptual framework should allow for future studies to refine our understanding of the molecular pathogenesis of PAH and improve the therapeutic regimen for this disease. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:14 / 30
页数:17
相关论文
共 239 条
[1]   Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats [J].
Abe, K ;
Shimokawa, H ;
Morikawa, K ;
Uwatoku, T ;
Oi, K ;
Matsumoto, Y ;
Hattori, T ;
Nakashima, Y ;
Kaibuchi, K ;
Sueishi, K ;
Takeshita, A .
CIRCULATION RESEARCH, 2004, 94 (03) :385-393
[2]   Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice [J].
Abe, Kohtaro ;
Tawara, Shunsuke ;
Oi, Keiji ;
Hizume, Takatoshi ;
Uwatoku, Toyokazu ;
Fukumoto, Yoshihiro ;
Kaibuchi, Kozo ;
Shimokawa, Hiroaki .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 48 (06) :280-285
[3]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[4]   Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension [J].
Achcar, ROD ;
Demura, Y ;
Rai, PR ;
Taraseviciene-Stewart, L ;
Kasper, M ;
Voelkel, NF ;
Cool, CD .
CHEST, 2006, 129 (03) :696-705
[5]   STIMULANT-INDUCED PULMONARY TOXICITY [J].
ALBERTSON, TE ;
WALBY, WF ;
DERLET, RW .
CHEST, 1995, 108 (04) :1140-1149
[6]   Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension [J].
Aldred, Micheala A. ;
Machado, Rajiv D. ;
James, Victoria ;
Morrell, Nicholas W. ;
Trembath, Richard C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (08) :819-824
[7]   BMPR2 Gene Rearrangements Account for a Significant Proportion of Mutations in Familial and Idiopathic Pulmonary Arterial Hypertension [J].
Aldred, Micheala A. ;
Vijayakrishnan, Jairam ;
James, Victoria ;
Soubrier, Florent ;
Gomez-Sanchez, Miguel A. ;
Martensson, Gunnar ;
Galie, Nazzareno ;
Manes, Alessandra ;
Corris, Paul ;
Simonneau, Gerald ;
Humbert, Marc ;
Morrell, Nicholas W. ;
Trembath, Richard C. .
HUMAN MUTATION, 2006, 27 (02) :212-213
[8]   CIRCULATING IMMUNOREACTIVE ENDOTHELIN-1 IN CHILDREN WITH PULMONARY-HYPERTENSION - ASSOCIATION WITH ACUTE HYPOXIC PULMONARY VASOREACTIVITY [J].
ALLEN, SW ;
CHATFIELD, BA ;
KOPPENHAFER, SA ;
SCHAFFER, MS ;
WOLFE, RR ;
ABMAN, SH .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (02) :519-522
[9]   Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease [J].
Aslan, M ;
Ryan, TM ;
Adler, B ;
Townes, TM ;
Parks, DA ;
Thompson, JA ;
Tousson, A ;
Gladwin, MT ;
Patel, RP ;
Tarpey, MM ;
Batinic-Haberle, I ;
White, CR ;
Freeman, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15215-15220
[10]   Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [J].
Atkinson, C ;
Stewart, S ;
Upton, PD ;
Machado, R ;
Thomson, JR ;
Trembath, RC ;
Morrell, NW .
CIRCULATION, 2002, 105 (14) :1672-1678